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involved in retrograde transport
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ABSTRACT
Searching and evaluating the Human Protein Atlas for
transmembrane proteins enabled us to identify an integral
membrane protein, TMEM115, that is enriched in the Golgi
complex. Biochemical and cell biological analysis suggested that
TMEM115 has four candidate transmembrane domains located in the
N-terminal region. Both the N- and C-terminal domains are oriented
towards the cytoplasm. Immunofluorescence analysis supports that
TMEM115 is enriched in the Golgi cisternae. Functionally, TMEM115
knockdown or overexpression delays Brefeldin-A-induced Golgi-to-
ER retrograde transport, phenocopying cells with mutations or
silencing of the conserved oligomeric Golgi (COG) complex. Co-
immunoprecipitation and in vitro binding experiments reveals that
TMEM115 interacts with the COG complex, and might self-interact to
form dimers or oligomers. A short region (residues 206–229)
immediately to the C-terminal side of the fourth transmembrane
domain is both necessary and sufficient for Golgi targeting.
Knockdown of TMEM115 also reduces the binding of the lectins
peanut agglutinin (PNA) and Helix pomatia agglutinin (HPA),
suggesting an altered O-linked glycosylation profile. These results
establish that TMEM115 is an integral membrane protein of the Golgi
stack regulating Golgi-to-ER retrograde transport and is likely to be
part of the machinery of the COG complex.
KEY WORDS: TMEM115, Golgi complex, Retrograde transport,
COG complex
INTRODUCTION
The Golgi complex is a central station of the secretory pathway
and plays a fundamental role in protein modifications such
as glycosylation and protein sorting to multiple post-Golgi
compartments (Glick and Nakano, 2009; Miller and Ungar,
2012; Rosnoblet et al., 2013b). The Golgi is dynamically linked
to the endoplasmic reticulum (ER) by retrograde Golgi-to-ER
transport, which is involved in the retrieval of resident ER
proteins (such as luminal KDEL-containing proteins) that have
escaped from the ER, as well as maintaining equilibrium of
cycling membrane proteins (such as ERGIC53, KDEL receptors,
p24 family proteins and SNAREs) in the early secretory pathway
(Fu¨llekrug et al., 1999; Tang et al., 1995; Tang and Wang, 2013;
Townsley et al., 1993). Retrograde transport from the endosomal
compartments to the Golgi also links the endocytic pathway
with the secretory pathway (Chia and Gleeson, 2011; Lieu and
Gleeson, 2011; Seaman, 2008; Seaman, 2009). Intracellular
transport in the secretory and endocytic pathways is tightly
regulated and involves the interactions of many organelles and
machineries so that cargoes are delivered from one compartment
to another while the integrity and the composition of proteins
and lipids across these organelles are carefully balanced and
maintained (Cancino and Luini, 2013). Both the anterograde and
retrograde transport pathways are crucial for the development and
maintenance of the normal physiology of an organism. Although
it is known that the secretory pathway is important for cell
growth, defects in retrograde transport can indirectly result in
the failure of the ER-to-Golgi transport pathway. It has been
proposed that the defective biosynthetic trafficking observed in
some yeast mutants of components of the conserved oligomeric
Golgi (COG) tethering complex might be an outcome of
secondary trafficking defects arising from primary retrograde
trafficking defects (Kim et al., 2001; Wuestehube et al., 1996).
The evolutionarily conserved COG complex has eight subunits
(COG1–COG8) and is implicated in the tethering of retrograde
Golgi vesicles for intra-Golgi transport as well as retrograde
endosome–Golgi transport. Accordingly, malfunctions in the
COG complex greatly impact on Golgi integrity, protein and lipid
trafficking and glycosylation (Miller and Ungar, 2012; Ungar
et al., 2006; Willett et al., 2013). The COG complex is organized
into two functionally and structurally distinct sub-complexes,
Lobe A (COG1–COG4) and Lobe B (COG5–COG8) (Laufman
et al., 2011; Lees et al., 2010; Loh and Hong, 2004; Walter et al.,
1998). Subunits of Lobe A are essential for growth in yeast.
Deletions or mutations of genes encoding these proteins cause
severe glycosylation defects. Conversely, deletions of Lobe
B subunits do not exhibit such severe phenotypes in yeast,
suggesting that the Lobe B subcomplex has a regulatory or
redundant role (Kudlyk et al., 2013; Richardson et al., 2009;
Zolov and Lupashin, 2005). It has recently been shown that
downregulation of COG function results in the mislocalization
and degradation of resident Golgi glycosyltransferases and/or
glycosidases (Smith and Lupashin, 2008). The COG complex is
intimately involved in glycosylation homeostasis. It maintains
a dynamic and finely tuned balance between anterograde and
retrograde trafficking by coordinating intra-Golgi retrograde
transport. This fine balance is required for the correct
localization and distribution of the glycosylation enzymes in the
Golgi (Reynders et al., 2011). The functional importance of the
COG complex in human is underscored by the identification of
mutations in six out of the eight subunits (COG1, COG4, COG5,
COG6, COG7 and COG8) in patients with the human disease
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congenital disorder of glycosylation (CDG) type II (Foulquier
et al., 2007; Foulquier et al., 2006; Freeze and Ng, 2011; Kranz
et al., 2007; Kudlyk et al., 2013; Ng et al., 2011; Spaapen et al.,
2005; Wu et al., 2004; Zeevaert et al., 2008). The patients are
characterized by abnormal glycosylation, although the clinical
presentations are highly heterogeneous. Cellular depletion of
COG subunits or fibroblasts derived from CDG type II patients
exhibit resistance to Brefeldin A (BFA)-induced Golgi-to-ER
retrograde transport and accelerated degradation of Golgi
proteins such as GS15, GS28 mannosidase II, GPP130, CASP,
giantin and golgin-84 (Oka et al., 2004; Steet and Kornfeld,
2006). In humans, mutations of both Lobe A and Lobe B
subcomplexes are associated with CDG, suggesting that the
entire complex is essential for proper function of the Golgi
complex to execute normal glycosylation of cargo proteins.
Here, we describe a new player in the Golgi-to-ER retrograde
transport pathway. TMEM115, also known as PL6, located on
chromosome 3p21.3, was originally thought to function as a
tumor suppressor (Ivanova et al., 2008). Our biochemical, cell
biological and functional studies suggest that TMEM115 is an
integral Golgi protein of ,35 kDa with four predicted
transmembrane domains. It interacts with COG4 of the COG
complex and is involved in proper O-linked glycosylation and
efficient Golgi-ER retrograde transport in response to BFA
treatment.
RESULTS
Identification of new candidate Golgi membrane proteins
The Human Proteins Atlas database (http://www.proteinatlas.
org/) was searched for the term ‘transmembrane protein’.
The search was conducted using version 5.0 and produced a
list of 3541 proteins, of which 103 had been validated by
immunohistological staining. Further examination of the tissue
expression pattern and subcellular localization of these 103
proteins on the database narrowed the list of candidate Golgi
proteins to 11. In depth examination of the subcellular labeling
patterns of these 11 proteins enabled us to focus on five proteins
with clear perinuclear Golgi-like labeling (C11orf87, TMEM115,
TMEM77, TMEM87A and TMEM17). We used BLAST to align
the sequence of these five proteins against proteins in the yeast
and fly databases and found that both TMEM115 and TMEM87A
have structural homologs in these organisms (the process
is outlined in supplementary material Fig. S1A). TMEM115
has been reported to have reduced expression in renal clear cell
carcinomas and other VHL-deficient tumors and to exhibit Golgi
localization (Ivanova et al., 2008). These observations suggest
that it might be a potential tumor suppressor located in the Golgi.
Therefore, we focused our study on TMEM115.
Hydrophobicity analysis of the TMEM115 sequence (351
residues) by TMpred (http://www.ch.embnet.org/software/
TMPRED_form.html) revealed four hydrophobic regions in
the N-terminal region (supplementary material Fig. S1B).
Alignment of amino acid sequences of TMEM115 from
human, mouse, frog, zebrafish, fly, worm and yeast revealed
they are well conserved throughout evolution. The C-terminal
region (residues 206–351) is hydrophilic in nature, within
which the epitope of the rabbit antibody used in the Atlas
study (HPA015497) is located (supplementary material Fig.
S1C). Accordingly, TMEM115 was predicted to have four
transmembrane domains with both N- and C-termini facing
either the cytoplasm (a model is shown in supplementary
material Fig. S1C) or the lumen.
TMEM115 is located at the Golgi complex
The endogenous levels of TMEM115 in various cell lines were
examined by western blotting. As shown in Fig. 1A, TMEM115
is ubiquitously expressed as a protein of ,35 kDa in the
examined cell lines; with the highest expression level in MDA-
MB-231 and Hs578t, both of which are invasive breast cancer
cells (Kirschmann et al., 1999; Paciotti and Tamarkin, 1988).
The subcellular distribution of TMEM115 was investigated
using immunofluorescence microscopy (Fig. 1B). TMEM115/
PL6 has previously been shown to exhibit a Golgi localization
(Ivanova et al., 2008). In our study, cells were double-labeled
with antibody against TMEM115 (Fig. 1B, panels b, e, h and k)
and other antibodies against various Golgi markers (Fig. 1B,
panels a, d, g and j). TMEM115 was found at the perinuclear
region, adjacent to, but not co-localized with the cis-Golgi matrix
protein GM130 (Nakamura et al., 1995) (Fig. 1B, panels c and c1)
or the trans-Golgi network (TGN) marker TGN46 (Ponnambalam
et al., 1996; Prescott et al., 1997) (Fig. 1B, panels l and l1). In
cells stably expressing either GFP-tagged mannosidase II (manII–
GFP), a medial-Golgi marker or the GFP–GalT chimera [in which
the catalytic domain of b1,4-galactosyltransferase 1 (GalT) is
replaced by GFP], a trans-Golgi marker (Colley, 1997; Rabouille
et al., 1995; Velasco et al., 1993), TMEM115 was found to
be well colocalized with manII–GFP (Fig. 1B, panels f and
f1) and the signal substantially overlapped with GalT–GFP
(Fig. 1B, panels i and i1). Immunoelectron microscopy analysis
showed that TMEM115 was localized to the Golgi complex and
was distributed towards the outer periphery of the Golgi
(supplementary material Fig. S2A, arrows). These results
indicate that TMEM115 is likely to be enriched in the Golgi
stack.
The C-terminal tail of TMEM115 is exposed in the cytoplasm
Evolutionary comparison and hydrophobicity analysis of its
primary amino acid sequence predict that TMEM115 has a short
cytoplasmic domain at the N-terminus, followed by four
transmembrane domains and a C-terminal hydrophilic tail of
,146 amino acid residues (supplementary material Fig. S1C),
which contains a predicted coiled-coil domain (Fig. 2A).
Immunofluorescence studies in semi-permeabilized cells (in
which only the plasma membrane is permeabilized but the
membrane of internal organelles such as the Golgi is intact) were
carried out to investigate the proposed membrane topology of
TMEM115, using an antibody that specifically recognizes an
epitope (residues 255–344) located in the C-terminal tail. Low
concentrations (5 mg/ml) of digitonin (Diaz and Stahl, 1989;
Eckhardt et al., 1999) were used to selectively permeabilize the
plasma membrane. The cells were then simultaneously labeled
with anti-GFP and anti-TMEM115 antibodies (Fig. 2B, panels a–
h), or with anti-GM130 and anti-TMEM115 antibodies (Fig. 2B,
panels i–p). As the catalytic domain of GalT is replaced by GFP
in the chimera GalT–GFP (Schaub et al., 2006), the GFP tag
is oriented to the lumen of the Golgi cisternae and is not
accessible to the GFP antibody when the Golgi membrane is not
permeabilized. Therefore if the C-terminal tail of TMEM115 is in
the lumen of the Golgi, it too cannot be accessed by the
TMEM115 antibody. In digitonin-treated cells, there were no
significant detection of anti-GFP (Fig. 2B, panels a and d),
indicating that the anti-GFP antibody was unable to react with the
epitope located in the lumen of an intact Golgi complex. In
contrast, the peripheral cytoplasmic protein GM130 (Nakamura
et al., 1995) was readily labeled in digitonin-permeabilized cells
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(Fig. 2B, panel i). Interestingly, TMEM115 was also clearly
detected in digitonin-treated cells (Fig. 2B, panels c and k). In the
parallel control experiment where cells were fully permeabilized
with 0.1% Triton-X 100 (Fig. 2B, panels e–h and m–p), all
antibodies were able to bind to their respective epitopes. The
intensity of the signals of TMEM115 and GM130 in fully
permeabilized cells were not increased as compared with those in
digitonin-permeabilized cells (Fig. 2B, panels c and g, k and o, i
and m). These results clearly show that anti-TMEM115 antibody
was able to fully access its epitope in semi-permeabilized cells,
establishing that the C-terminal region of TMEM115 is oriented
towards the cytoplasm (supplementary material Fig. S1C).
Proper expression level of TMEM115 is required for BFA-
induced Golgi-to-ER retrograde transport
To study the function of TMEM115, we silenced its protein
expression using siRNA. Fig. 3A shows (for triplicate samples)
that TMEM115 expression was effectively knocked down
(Fig. 3A, panel I) and the level of knockdown can be
maintained in the cells for at least 6 days post siRNA
transfection (Fig. 3A, panel II). Immunofluorescence analysis
also showed that the perinuclear staining of TMEM115 was also
greatly reduced (Fig. 3B, panel d).
We then examined the effect of TMEM115 depletion
on various Golgi-associated functions [such as the Golgi
morphology, vesicular stomatitis virus G protein (VSV-G)
transport and BFA-induced Golgi-to-ER transport] and found
that the Golgi complex became more compact (Fig. 3B, panel e)
and that BFA-induced Golgi disassembly was affected (Fig. 3C).
VSV-G protein transport in TMEM115-silenced cells did not
exhibit any difference to the control cells (data not shown). To
follow BFA-induced Golgi-to-ER retrograde transport, control
and TMEM115-silenced cells were incubated with 5 mg/ml
BFA at 37 C˚ for various times. The redistribution of
TMEM115 and the Golgi marker GalT–GFP were visualized by
immunofluorescence microscopy (Fig. 3C). In control cells
(Fig. 3C, top panels), both TMEM115 and GalT–GFP were
found in tubule-like structures spreading out from the perinuclear
Golgi region after incubation with BFA for 10 minutes. By
30 minutes, the majority of GalT–GFP had been redistributed
Fig. 1. Endogenous expression and subcellular localization of
TMEM115. (A) Endogenous expression of TMEM115 in various cell
lines. (B) Subcellular localization of endogenous TMEM115.
Endogenous TMEM115 was colabeled with endogenous GM130
(panels a–c and c1) or TGN46 (panels j–l and l1) in HeLa cells. In
addition, endogenous TMEM115 was colabeled with mannosidase II
(manII)–GFP in HeLa cells stably expressing manII–GFP (panels
d–f and f1), or GalT in HeLa cells stably expressing GalT–GFP
(panels g–i and i1). Scale bar: 10 mm.
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into an ER-like labeling pattern, whereas TMEM115 was found
in both the perinuclear region and diffuse punctated structures. By
45–60 minutes, TMEM115 had been redistributed in punctated
structures scattered throughout the cytoplasm. In marked contrast,
GalT–GFP was found in a tight, compact structure at the
perinuclear region in TMEM115 knocked-down cells 10–
20 minutes after treatment with BFA. This labeling pattern of
GalT–GFP persisted even after 30 minutes of incubation with
BFA, after which the protein gradually redistributed to an ER-like
pattern (at 45 and 60 minutes). Even after 45–60 minutes
incubation, GalT–GFP had not completely re-distributed back
to the ER (Fig. 3C, bottom panels). The quantification of
these experiments was shown in Fig. 3D. Similar results were
also observed in other cell lines, such as A549, H460 using
endogenous Golgi proteins such as giantin and GPP130 (data not
shown), suggesting that silencing of TMEM115 markedly delays
BFA-induced Golgi-to-ER retrograde transport.
The BFA-dependent Golgi disassembly was also examined
in cells transiently overexpressing exogenous full-length
TMEM115 (TMEM115-FL). Fig. 3E shows that transiently
expressed TMEM115-FL was located to the Golgi complex and
colocalized with GalT–GFP (Fig. 3E, panels a–c). Interestingly,
when cells were treated with BFA for 30 minutes, both GalT–
GFP and TMEM115-FL were found in a compact structure at the
perinuclear region, whereas in the surrounding untransfected
cells, GalT–GFP was efficiently redistributed to the ER (Fig. 3E,
panels d–f). This delay of BFA-induced Golgi disassembly is
similar to that in TMEM115 knocked-down cells. The strength of
inhibition of BFA induced Golgi redistribution also correlates
with the level of expression of this construct [i.e. the higher the
expression of TMEM115-FL, the slower the rate of BFA-induced
Golgi redistribution (supplementary material Fig. S3A, panels
a and b, asterisks)]. These observations suggest that both
overexpressing and silencing TMEM115 inhibits BFA-induced
Golgi disassembly; therefore, BFA-induced Golgi-to-ER
retrograde transport might require finely regulated levels of
TMEM115.
To rule out any possibility of off-target effects in the siRNA
experiments, we proceeded to validate the effect of TMEM115
silencing in cells by using specific siRNAs from the siRNA pool
against TMEM115. Immunoblotting analysis results showed that,
of the four siRNAs, siRNA 3 had the least efficiency in silencing
Fig. 2. The C-terminal
portion of TMEM115 is
exposed in the cytoplasm.
(A) Schematic illustration of
the predicted structure of
TMEM115. TM,
transmembrane domain;
CC, coiled-coil domain.
(B) The C-terminal part of
TMEM115 is exposed in the
cytoplasm. HeLa cells
stably expressing GalT–
GFP cells were
permeabilized by 5 mg/ml
digitonin (panels a–d, i–l) or
0.1% Triton-X (panels e–h,
m–p). Scale bar: 10 mm.
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Fig. 3. See next page for legend.
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TMEM115 (Fig. 3F, Fig. 3G, panel e). It also did not affect the
redistribution of GalT–GFP to the ER in the presence of BFA,
similar to control cells (Fig. 3F, panel w). By contrast, the other
three siRNA duplexes were able to knockdown TMEM115
efficiently, and also had an inhibitory effect on GalT–GFP
redistribution to the ER, similar to that of the pooled TMEM115
siRNA (Fig. 3G). In addition, the Golgi complex (marked by
GalT–GFP) appeared to be more compact in TMEM115-silenced
cells as compared to the control cells. Similar to the Golgi
disassembly assay by BFA, the degree of compactness correlates
to the level of TMEM115 silencing. siRNA 3, which has the least
efficiency for TMEM115 silencing, shows the least compact in
Golgi morphology (Fig. 3G; supplementary material Fig. S3B).
Silent mutations were introduced into TMEM115–FLAG to
make it resistant to one (siRNA 1) of the siRNAs used in our
experiments. Expression of TMEM115 in the knockdown cells
could be rescued by the exogenous siRNA-resistant construct
(TMEM115 si#1R-FLAG) as shown by immunofluorescence
(supplementary material Fig. S4A, panels i and l) and western
blotting (supplementary material Fig. S4B). Similar to wild type,
TMEM115 si#1R-FLAG, when expressed at very high levels,
disrupts the Golgi complex (supplementary material Fig. S4A,
panel a,b, panel i–j, #). In cells that highly expressed TMEM115
si#1R-FLAG (supplementary material Fig. S4A, cells marked
with #), the entire Golgi (labeled by GalT–GFP) was dispersed
throughout the cell. However, when expressed at a moderate
level, siRNA-resistant TMEM115 was located at the Golgi
complex and colocalized with GalT–GFP (supplementary material
Fig. S4A, panels a–d; panels i–l, arrowheads). In control cells,
upon 10 minutes treatment with BFA, both the FLAG-tagged
protein and GalT–GFP were observed in a compact structure at
the perinuclear region in 91% of the cells that were moderately
expressing TMEM115 si#1R-FLAG, whereas in the surrounding
untransfected cells, GalT–GFP was efficiently redistributed to the
ER (supplementary material Fig. S4A, panel f). This delay effect
on the BFA-induced Golgi-to-ER retrograde transport is similar to
that caused by the silencing of TMEM115 (supplementary
material Fig. S4A, panel n, arrow). Therefore, it seems that the
BFA-dependent Golgi-to-ER retrograde transport is regulated by a
finely balanced amount of TMEM115. The expression of
TMEM115 si#1R-FLAG in TMEM115-silenced cells appears to
be able to rescue this delayed phenotype in some (supplementary
material Fig. S4A, panels m and n, asterisks), but not all cells
expressing the FLAG-tagged TMEM115. However, we are unable
to differentiate whether this reversion to a wild-type phenotype is
due to a true rescue event or due to the fact that the Golgi was
already disrupted by a high level expression of TMEM115 si#1R-
FLAG.
The effect of TMEM115 depletion on BFA-dependent Golgi
disassembly is similar to the phenotype observed in cells deficient
in COG proteins (Kranz et al., 2007; Steet and Kornfeld, 2006) or
upon silencing COG subunits (Laufman et al., 2011; Laufman
et al., 2013; Laufman et al., 2009), indicating that TMEM115
might play certain functions in COG-dependent transport
pathways. Taken together, these results strongly suggest that
TMEM115 functions in regulating or directly involved in the
retrograde transport from the Golgi to the ER.
TMEM115-FL interacts with b-COP, COG proteins and
ERGIC53
To understand the function of TMEM115 in Golgi-to-ER
transport, we investigated its potential interacting partners,
using co-immunoprecipitation and immunoblotting (Fig. 4).
Fig. 4A showed that FLAG-tagged TMEM115-FL was
efficiently immunoprecipitated and both endogenous proteins of
b-COP and COG3 were specifically co-immunoprecipitated.
TMEM115-FL was able to co-immunoprecipitate ERGIC53–
GFP and vice versa (Fig. 4B). Additional negative controls for
TMEM115 interactions are shown in supplementary material
Fig. S2C. p230 (also known as GOLGA4) and golgin-84 (also
known as GOLGA5) were not co-immunoprecipitated by
TMEM115. p230 is a Golgi peripheral protein (Kjer-Nielsen
et al., 1999), whereas golgin-84 is a single-transmembrane
Golgi integral protein (Bascom et al., 1999). Taken together,
these data indicate that the interactions of TMEM115 and its
various interacting partners (ERGIC53, b-COP and COG3) are
specific.
We further examined whether TMEM115-FL also interacts
with other subunits of the COG complex (Fig. 4C). The
results demonstrated that all eight COG subunits were each
co-immunoprecipitated with TMEM115-FL, with varying
efficiencies. To investigate which domains of TMEM115
interact with COG proteins, we generated two C-terminally
FLAG-tagged deletion mutants (Fig. 4D). TMEM115-NT229
consists of the first 229 residues of TMEM115, thus containing
all the four candidate transmembrane domains. TMEM115-
230CT contains the C-terminal tail (residues 230–351). Fig. 4E
shows that both TMEM115-NT229 and TMEM115-230CT were
able to co-immunoprecipitate endogenous COG3 and b-COP.
TMEM115-230CT was also able to co-immunoprecipitate all
eight transfected Myc-tagged COG proteins (Fig. 4F).
Fig. 3. BFA-induced Golgi disassembly is delayed in both TMEM115-
silenced and TMEM115-overexpressing cells. (A) TMEM115 is effectively
silenced using siRNA. (I) Pooled siRNA targeting TMEM115 (lane 1–3) or
control pooled non-targeting siRNA (lane 4–6) was transfected into HeLa
cells. Cell lysates were harvested 72 hours after transfection. (II) HeLa cells
were transfected with pooled siRNA targeting TMEM115 or control pooled
non-targeting siRNA. Cell lysates were harvested at the indicated time after
transfection. (B) Pooled siRNA targeting TMEM115 (panels d–f) or control
pooled non-targeting siRNA (panels a–c) was transfected into HeLa cells
stably expressing GalT–GFP. 72 hours after transfection, cells were
examined by immunofluorescence microscopy. (C) BFA-induced Golgi
disassembly is delayed in TMEM115-silenced cells. HeLa cells stably
expressing GalT–GFP were transfected with either pooled siRNA targeting
TMEM115 (lower panels) or control pooled non-target siRNA (upper panels).
72 hours after transfection, cells were incubated with 5 mg/ml BFA at 37˚C for
the indicated length of time. (D) HeLa cells stably expressing GalT–GFP
were transfected with control or TMEM115-specific siRNA. The numbers of
cells that exhibit Golgi staining after 10 minutes of 5 mg/ml BFA treatment at
37˚C were quantified. Control KD, n51221; TMEM115 KD, n5980.
*P,0.0001. (E) BFA-induced Golgi disassembly is delayed in TMEM115-
overexpressing cells. C-terminally FLAG-tagged full-length TMEM115
(TMEM115-FL-FLAG) was transfected into HeLa cells stably expressing
GalT–GFP. Cells were then incubated with 5 mg/ml BFA at 37˚C for
30 minutes. 100% of transfected cells that expressed moderate levels of
TMEM115-FL-FLAG exhibited a Golgi retention phenotype after BFA
treatment (n515). (F) Individual siRNAs from the siRNA pool were used to
target TMEM115. Pooled siRNA targeting TMEM115 (lane 1) or control
pooled non-target siRNA (lane 2) or individual siRNA duplexes targeting
TMEM115 (lanes 3–6) were transfected into HeLa cells. Cells were
harvested 72 hours after transfection. The lysates were analyzed for the
level of TMEM115 by western blotting. (G) BFA-induced Golgi disassembly
assay. Pooled siRNA targeting TMEM115 or control pooled non-target siRNA
or each individual siRNA duplex targeting TMEM115 was transfected into
HeLa cells stably expressing GalT–GFP. Cells were then incubated with
5 mg/ml BFA at 37˚C for 0 minutes (upper panels) or 30 minutes (lower
panels). Scale bar: 10 mm.
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Fig. 4. See next page for legend.
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We further investigated the interactions between TMEM115
and the COG complex by in vitro binding assays. TMEM115 and
the eight COG subunits were individually translated in vitro. Each
of the translated COG proteins were then added with the
translated full-length TMEM115–FLAG–HIS and subjected to
FLAG immunuoprecipitation (Fig. 4G). The middle panel
shows that at normal salt washing concentration (150 mM
NaCl); TMEM115 was able to co-immunoprecipitate all eight
COG subunits albeit with different efficiencies. However, when
subjected to a higher salt washing concentration (500 mM NaCl),
only COG4 was co-immunoprecipitated by TMEM115 (Fig. 4G,
lower panel, red asterisk), indicating that TMEM115 has the
highest affinity to COG4. These results suggest that TMEM115 is
an interacting partner of the COG tethering complex and its
interaction with the complex is likely through direct interaction
with COG4, although additional experiments are needed to
validate this.
TMEM115 self-interacts through its N-terminal portion
Given that TMEM115 contains four candidate transmembrane
domains and a coiled-coil domain, we speculated that the protein
might be able to dimerize or oligomerize. To examine whether
TMEM115 forms oligomers, we generated six additional deletion
mutants of the protein. A graphical representation of all the
deletion mutants is shown in Fig. 5A. The ability of each deletion
mutant to co-immunoprecipitate the C-terminally Myc-tagged
full-length TMEM115 (TMEM115–Myc) was accessed. Fig. 5B
shows that TMEM115–Myc was co-immunoprecipitated with
FLAG-tagged full-length TMEM115, as well as with most of
the TMEM115 mutants, indicating that TMEM115 can form
dimers or homo-oligomers. However, TMEM115–Myc was
not found to interact with the C-terminal tail of TMEM115
(TMEM15-206CT and TMEM115-230CT). These results indicate
that TMEM115 forms homo-dimer or -oligomers through the N-
terminal region.
The C-terminal tail of TMEM115 contains a Golgi-targeting
signal within the region of residues 206–229
To determine which region of TMEM115 is important for
Golgi targeting, the subcellular localization of the various
mutants were examined. We focused our analysis on cells
expressing moderate levels of exogenous proteins. Exogenously
expressed full-length TMEM115 exhibited a perinuclear
staining (Fig. 6, panel a) which colocalized with GalT–GFP,
similar to that of the endogenous protein (Fig. 3B). Mutants
harboring mutations in the coiled-coil domain (TMEM115-
DCC, TMEM115-A1 and TMEM115-A2) did not affect
the Golgi localization of TMEM115 (Fig. 6, panels m, o and
q, asterisks), indicating that the coiled-coil domain does
not directly participate in the targeting the protein to the
Golgi. TMEM115-NT205, which contains the four predicted
transmembrane domains, would be expected to be localized to
the membrane, whereas the TMEM115-206CT fragment
would be predicted to be expressed as a cytosolic protein.
Surprisingly, TMEM115-NT205 showed an ER-like staining,
whereas TMEM115-CT206 exhibited some Golgi staining
which partially colocalized with GalT–GFP (Fig. 6, panel g,
asterisk). These results suggest that the Golgi localization
signal is contained between the end of the fourth
transmembrane domain (amino acid 206) and the start of the
coiled-coil domain (amino acid 281) of TMEM115. TMEM115-
NT229 (a longer version of TMEM115-NT205) was observed
at the Golgi complex, whereas the reciprocate shorter C-
terminal mutant TMEM115-230CT did not show the Golgi
staining. These results suggest that residues 206–229 might
contain an ER export and/or Golgi-targeting signal. This
conclusion is further supported by the finding that
TMEM115-205D, which lacks only residues 206–229, did not
localize to the Golgi but exhibited an ER-like staining (Fig. 6,
panel k).
To further validate the role of residues 206–229, we generated
a CD8 reporter protein, in which the cytoplasmic tail of CD8 was
replaced with the fragment 206–229 of TMEM115 (Fig. 7A).
This chimera is called CD8–TM115. This approach has been
used previously to functionally test the targeting function of
cytoplasmic tails (Seaman, 2004). CD8 is a cell surface protein
that is not normally expressed in HeLa cells and it does not
appear to have intrinsic targeting information in the intracellular
organelles. In CD8–furin, the cytoplasmic tail of CD8 is replaced
by that of furin. The cytoplasmic tail of furin has previously been
shown to mediate the targeting of the CD8–furin chimera to the
Golgi (Hirst et al., 2005). Therefore, if residues 206–229 of
TMEM115 functions only as an ER export signal, the chimera
CD8–TM115 would be expected to target to the plasma
membrane, whereas, if it contains a Golgi-targeting signal, then
the chimera would be retained in the Golgi.
Wild-type CD8 was targeted to the plasma membrane (Fig. 7B,
panel a), whereas CD8-–furin chimera was found at the Golgi,
colocalized with GalT–GFP (Fig. 7B, panel d). CD8–TM115 was
also found to colocalize with GalT–GFP at the perinuclear region.
Additionally, there are some CD8–TM115 signals at a lower
density found at the plasma membrane and punctated structures
(Fig. 7B, panel g). These results suggest that the fragment 206–
229 of TMEM115 contains a signal that is necessary and
sufficient for Golgi targeting.
Fig. 4. TMEM115 associates with proteins involved in retrograde
trafficking. (A) TMEM115-FL-FLAG interacts with endogenous COG3 and b-
COP. TMEM115-FL-FLAG was transfected into HEK293 cells. Lysates
derived from control cells (Ctrl, lanes 2 and 4) or transfected cells (FL, lanes
1 and 3) were subjected to FLAG immunoprecipitation (IP). (B) TMEM115-
FL–FLAG interacts with ERGIC53–GFP. HEK293 cells were transfected with
TMEM115-FL–FLAG and either GFP empty vector or ERGIC53–GFP. Cell
lysates were subjected to FLAG or GFP immunoprecipitation. (C) TMEM115
interacts with all COG subunits. HEK293 cells were transfected with
TMEM115-FL–FLAG and either empty vector or each of Myc–COG proteins.
Cell lysates were subjected to FLAG immunoprecipitation. (D) Schematic
illustration of the FLAG-tagged TMEM115 full-length and mutants. All proteins
are C-terminally tagged with FLAG. TMEM115-FL, full-length TMEM115;
TMEM115-NT229 contains residues 1–229 of TMEM115; TMEM115-230CT
contains residues 230–252. TM, transmembrane domain; CC, coiled-coil
domain. (E) TMEM115 can co-immunoprecipitate COG3 and b-COP through its
N- and C-terminal portion. HEK293 cells were transfected with TMEM115-FL,
TMEM115-NT229 or TMEM115-230CT. Cell lysates were subjected to FLAG
immunoprecipitation. The immunoprecipitates were analyzed by immunoblotting
as indicated. The red arrowheads indicate the respective FLAG-tagged
TMEM115 proteins. (F) The C-terminal tail of TMEM115 interacts with all COG
subunits. HEK293 cells were transfected with TMEM115-230CT and either
empty vector or each of Myc–COG proteins. Cell lysates were subjected to
FLAG immunoprecipitation. (G) TMEM115 binds to COG4 with the highest
affinity. TMEM115 and the eight COG subunits were individually translated in
vitro. Each of the translated COG proteins was then added to the translated full-
length TMEM115–FLAG–HIS and subjected to FLAG immunoprecipitation. The
beads were washed with cell lysis buffer containing either 150 mM or 500 mM
NaCl. The immunoprecipitates were analyzed by immunoblotting as indicated.
The white asterisks indicate respective in vitro translated Myc-tagged COG
proteins. The red asterisks indicate Myc-tagged COG4.
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Silencing TMEM115 affects glycosylation
It has been reported that glycosylation is affected in COG-
deficient cells (Kranz et al., 2007; Reynders et al., 2011;
Rosnoblet et al., 2013b; Zeevaert et al., 2008). Given that
TMEM115 interacts with COG proteins and its knockdown also
phenocopies COG mutant cells in BFA-induced Golgi-to-ER
retrograde transport (Kranz et al., 2007; Laufman et al., 2011;
Laufman et al., 2013; Laufman et al., 2009; Steet and Kornfeld,
2006), we proceeded to investigate whether glycosylation was
also affected in TMEM115 knocked-down cells. TMEM115-
silenced cells were fixed and labeled with fluorescent-dye-
conjugated lectins (Fig. 8A). The immunofluorescence results
showed that there were no obvious difference in the intensity
and labeling pattern of Concanavalin A (ConA) or wheat germ
agglutinin (WGA). Surface, but not Golgi, labeling by Helix
pomatia agglutinin (HPA) was reduced, whereas surface
labeling by peanut agglutinin (PNA) was almost completely
ablated in the TMEM115 knocked-down cells. We also
compared the cell surface biotinylation profile between
TMEM115-silenced cells and control cells using surface
biotinylation, lectin-binding and immunoblotting analysis
(Fig. 8B). Total glycosylation appeared to be reduced in the
knockdown cells. ConA-binding glycoproteins were decreased,
albeit to a lesser extent as compared to that of PNA binding.
ConA, WGA and HPA binds N-linked glycans (Molin
et al., 1986; Nagata and Burger, 1974; Sharon, 1983; Sheldon
et al., 1998), whereas PNA binds to O-linked glycans (Lotan
et al., 1975). However, it has been recently shown that
Fig. 5. TMEM115 self-interacts via
the N-terminal region.
(A) Schematic illustration of
TMEM115 full-length and the various
mutants. All proteins were C-
terminally tagged with FLAG.
TMEM115-FL, full-length TMEM115;
TMEM115-NT229 contains residues
1–229 of TMEM115; TMEM115-
230CT contains residues 230–252.
TMEM115-NT205 contains residues
1–205; TMEM115-206CT has
residues 206–252. Residues 206–
229 were deleted in TMEM115-205D
construct. The coiled-coil domain,
residues 281–301, was deleted in
TMEM115-DCC. Residues 281–285
(ERRRQ) was replaced by alanine
residues in TMEM115-A1; residues
286–295 (LALKALNERL) was
replaced by alanine residues in
TMEM115-A2. TM, transmembrane
domain; CC, coiled-coil domain.
(B) TMEM115 forms homo-oligomers
through its N-terminal portion.
HEK293 cells were transfected with
C-terminally Myc-tagged full-length
TMEM115 (TMEM115-myc) and
either empty vector or FLAG–
TMEM115 mutants. Cell lysates
were subjected to FLAG
immunoprecipitation (IP). The
immunoprecipitates were analyzed
by immunoblotting as indicated. All
mutants containing the intact N-
terminal 205 residues displayed
interaction with TMEM115-FL;
whereas the two C-terminal
fragments lacking the
transmembrane regions showed
no interaction.
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HPA was also capable of recognizing O-linked N-
acetylglucosamine (O-GlcNAc)-containing glycoproteins
(Rambaruth et al., 2012). These results suggest that the
function of TMEM115, either directly or indirectly, is
required for proper glycosylation to occur within the cell,
especially for O-linked glycosylation.
Fig. 6. Residues 206–
229 of TMEM115
contain a Golgi-
targeting signal.
FLAG-tagged
TMEM115 and its
mutants were
expressed in
transfected HeLa cells
stably expressing
GalT–GFP cells and
the localization of the
mutants was shown
together with GalT–
GFP. The percentage
of cells expressing
Golgi localization for
each mutant is also
shown. n, number of
cells counted. TM,
transmembrane
domain; CC, coiled-coil
domain. Scale bar:
10 mm.
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DISCUSSION
TMEM115 is a multi-transmembrane domain protein, which is
located at the Golgi complex (Ivanova et al., 2008). In this study,
we found that TMEM115 is likely localized at the medial- and
trans-Golgi cisternae and that the protein is oriented in such a way
that the C-terminal tail is exposed in the cytoplasm. Moreover,
silencing of TMEM115 using siRNA leads to a delay in Golgi-to-
ER retrograde transport in the presence of BFA, suggesting
that TMEM115 might play a role in regulating this trafficking
pathway. Surprisingly, transient overexpression of exogenous
TMEM115 also causes a similar delay, indicating that a
finely maintained expression level of TMEM115 is required
for efficient BFA-sensitive Golgi-to-ER retrograde transport.
Exogenously expressed TMEM115 was able to co-
immunoprecipitate both b-COP and the COG complex, two of
the key players regulating Golgi-to-ER retrograde trafficking
pathway (Oka et al., 2004), suggesting that TMEM115 might
participate in the regulation of the COPI- and COG-dependent
Golgi-to-ER retrograde trafficking pathway.
A series of deletion mutants was created to study the functional
domains of TMEM115. Interestingly, the mutant TMEM115-
206CT, which does not contain any transmembrane domain and
thus was expected to be expressed as a cytosolic protein, was
found to target to the Golgi complex. Further investigation
showed that when residues 206–229 were removed, the mutant
lost its Golgi localization. These 24 amino acids, when added
back to the ER-localized mutant (TMEM115-NT205), were able
to target the longer version (TMEM115-NT229) to the Golgi
complex. When the cytosolic tail of the plasma membrane protein
CD8 was replaced with residues 206–229 of TMEM115, the
resulting chimera CD8–TM115 was targeted to the Golgi
complex instead of the plasma membrane, indicating that an
autonomous Golgi-targeting signal is located within these 24
residues.
The TMEM115 expression profile in cancer cell lines shows
that TMEM115 seems to be expressed at a higher level in
invasive breast cancer cells, such as MDA-MB-231 and Hs578T;
as compared to MCF7, a weakly invasive breast cancer cell line.
Fig. 7. Residues 206–229 of TMEM115
are sufficient for Golgi targeting.
(A) Schematic illustration of various
chimeric CD8 proteins. CD8, full-length
wild-type human CD8; CD8–furin, the
cytoplasmic tail of CD8 was replaced
with the cytoplasmic tail of furin; CD8–
TM115, the cytoplasmic tail of CD8 was
replaced with the fragment 206–229 of
TMEM115. TM, transmembrane domain.
(B) Steady state distribution of CD8 or
CD8 chimeras in HeLa cells. These
proteins were transfected into HeLa cells
stably expressing GalT–GFP cells. The
chimeras were visualized by staining
with anti-CD8 antibody. The percentage
of cells expressing Golgi localization for
each chimera is also shown. n, number
of cells counted. Scale bar: 10 mm.
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When TMEM115 expression was reduced in MDA-MB-231 cells
using siRNA, a substantial inhibitory effect on the growth of
these cells was observed (data not shown). These results suggest
that there might be an association between elevated TMEM115
expression level and cancer cell properties. However, by contrast,
it has been reported that there is a loss of TMEM115 expression
in renal clear cell carcinomas and other VHL-deficient tumors
(Ivanova et al., 2008). The reason for this discrepancy is not clear,
but it is possible that it is specific to the cell type. Future studies
will be necessary to explore these possibilities.
Both the N-terminal transmembrane-containing mutant
(TMEM115-NT229) and the cytosolic domain mutant (TMEM115-
230CT) were able to interact with b-COP and COG3. Given that
TMEM115 seems to be able to self-oligomerize through its N-
terminal domain (Fig. 5B), it is likely that NT229 might be able to
form a complex with wild-type TMEM115 and thus be able to pull-
down COG3 and b-COP. Interestingly, even though the cytosolic
230CT does not interact with wild-type TMEM115 (Fig. 5B), it was
still able to pull-down COG3 and b-COP. This indicates that
TMEM115 might interact with COG3 and b-COP through the C-
terminal domain. We have also shown that TMEM115 binds to
COG4 with the highest affinity amongst the subunits of the COG
complex. Therefore it is likely that associations of TMEM115 with
the other COG subunits and the proteins involved in the retrograde
transport pathway might be through its interactions with COG4.
Glycosylation appears to be defective in TMEM115-silenced
cells, especially the glycosylation of PNA-binding glycans. PNA
binds to terminal Gal-b1-3 acetylgalactosamine, a common O-
linked glycoprotein motif (Maupin et al., 2012; Sheikh et al.,
1999). The lack of PNA staining on TMEM115-silenced cells
Fig. 8. Gene silencing of TMEM115
affects glycosylation. (A) Glycosylation is
affected in TMEM115 knocked-down cells.
HeLa cells stably expressing GalT–GFP
were transfected with either pooled siRNA
targeting TMEM115 (right panels) or control
pooled non-target siRNA (left panels). Non-
permeabilized cells were labeled with
fluorescent-dye-conjugated lectins. HPA
mainly stains the Golgi complex
(Campadelli et al., 1993; Virtanen, 1990)
with very weak staining at the cell surface
(de Albuquerque Garcia Redondo et al.,
2004). Therefore, for proper visualization of
HPA labeling, the cells were permeabilized
with 0.1% Triton-X-100 prior to staining.
Scale bar: 10 mm. (B) HeLa cells were
transfected with either control non-target
siRNA or TMEM115 siRNA. 72 hours after
transfection, cells were surface-biotinylated
and harvested. Cell lysates were incubated
with streptavidin–agarose beads and
biotinylated proteins were then eluted from
streptavidin–agarose beads and incubated
with either Concanavalin A (ConA)–
agarose beads or PNA–agarose beads.
Proteins were resolved by SDS-PAGE and
visualized by western blotting using
streptavidin–HRP.
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suggests that the presence of O-linked glycoproteins on the
cell surface was greatly reduced. O-linked glycans have been
implicated in multiple and diverse biological functions
(Brockhausen, 2006; Hang and Bertozzi, 2005; Tarp and
Clausen, 2008; Tian and Ten Hagen, 2009). O-glycosylation
can substantially increase the hydrophilicity and turgidity of cell
surface glycoproteins and can affect the adhesive properties of
cells or create binding sites for glycoproteins (Hang and Bertozzi,
2005; Ley and Kansas, 2004). There have been numerous reports
regarding the association between cancerous transformations
and an increase in short O-glycans, perhaps because disturbance
in cell adhesion could facilitate cell migration and metastasis
(Brockhausen, 2006; Itzkowitz et al., 1990; Nakamori et al., 1993;
Ogata et al., 1998). Changes in the cell surface glycosylation
profile are often associated with malignant transformation in
cancer (Hakomori, 2002; Hakomori and Cummings, 2012; Ono
and Hakomori, 2004). Regulation of O-glycosylation is thought to
depend mostly on the expression levels of the initiating GalNAc-T
enzyme. Recently, it has also been suggested that the COPI-
dependent Golgi-to-ER relocation of initiation GalNac-T enzyme
provides another mode of regulation for this glycosylation process
(Gill et al., 2010; Gill et al., 2011).
Recently, TMEM165, a novel six transmembrane Golgi protein
with no known biological function to date, has been identified to be
involved in CDG type II. Mutations in TMEM165 were observed
in patients with Golgi glycosylation defects. These mutations
crucially changed the subcellular localization of the protein,
suggesting that the glycosylation defects observed might be
secondary, and that the primary defect could exist outside the
glycosylation machinery. Zeevaert and colleagues proposed that
TMEM165 is a member of the ‘CDG plus’ subgroup. This group
encompass CDG that results from deficiencies of proteins that are
not specifically involved in glycosylation but that have functions in
the organization and homeostasis of the intracellular compartments
and the secretory pathway (Foulquier, 2009; Foulquier et al., 2012;
Rosnoblet et al., 2013a; Zeevaert et al., 2013), such as the COG
proteins (Foulquier, 2009), SEC23B (Bianchi et al., 2009) and
ATP6V0A2 (Guillard et al., 2009).
In summary, this study shows that TMEM115 contains
several functional domains: the N-terminal domain, which has
several transmembrane domains and mediates the formation of
TMEM115 homo-oligomers; residues 206–229, which contain an
autonomous Golgi-targeting signal; and its cytosolic C-terminal
tail, which mediates interaction with the cytosolic proteins of the
retrograde transport machinery, such as the coat complex COPI
and the tethering factor COG complex. O-linked glycosylation
was shown to be greatly reduced in TMEM115 knocked down
cells, although the mechanism by which TMEM115 silencing
alters O-glycosylation has yet to be defined. One could speculate
that because TMEM115 participates in the regulation of Golgi-to-
ER retrograde transport, a defect in this trafficking pathway
would thereby in turn affect the distribution and/or localization
of glycosylation enzymes that are necessary for effective
glycosylation. Therefore, TMEM115 might be a new member
of the CDG subgroup ‘CDG plus’, and future analysis of human
patients displaying a CDG phenotype for possible mutations of
TMEM115 will be of interest.
MATERIALS AND METHODS
Cell lines
The HeLa-GalT-GFP stable cell line was a gift from Jack Rohrer
(Friedrich Miescher Institut, Basel, Switzerland). HeLa-manII-GFP was a
gift from Frederick Bard (Institute of Molecular and Cell Biology,
Singapore). All other cell lines were obtained from American Type
Culture Collection (Manassas, VA, USA).
Antibodies and other materials
Antibodies against the following proteins were from the following
sources: actin and Myc (Santa Cruz Biotechnology); HA (Roche);
GM130 and CD8 (BD); mouse TMEM115 (Abnova); TMEM115,
TGN46, FLAG and FLAG-conjugated agarose beads (Sigma-Aldrich);
b-COP (Thermo Scientific); Golgin97 and COG3 were in-house
antibodies (Loh and Hong, 2004; Lu et al., 2004). Fluorochrome-
conjugated secondary antibodies were from Invitrogen and horseradish
peroxidase (HRP)-conjugated secondary antibodies were from Jackson
ImmunoResearch Laboratories, Inc. Brefeldin A was from Epicentre
Biotechnologies. Digitonin and agarose-bound lectins were purchased
from Sigma-Aldrich; fluorescent-dye-conjugated lectins were from
Vector Laboratories. The TMEM115 human cDNA ORF (accession
number NM_007024) was obtained from OriGene USA. GFP–ERGIC53
plasmid was a kind gift from Hans-Peter Hauri (University of Basel,
Switzerland).
Transfection and gene silencing
All plasmid transfections were performed using Effectene. All siRNA
duplexes were of the ON-TARGETplus SMARTpool type obtained
from Dharmacon RNAi Technologies. siRNA duplexes were transfected
into cells using RNAiMAXTM transfection reagent according to
manufacturer’s protocol.
Immunofluorescence microscopy
Cells grown on coverslips were washed twice with PBSCM (PBS
supplemented with 1 mM CaCl2 and 1 mM MgCl2) and then fixed in
PBSCM containing 3% paraformaldehyde for 20 minutes. Fixed cells
were washed five times at 5-minute intervals with PBSCM. The cells
were permeabilized with 0.1% saponin (Sigma) in PBSCM for
15 minutes. Cells were then immunolabeled with appropriate primary
antibodies diluted in fluorescence dilution buffer (PBSCM with 5% FBS
and 2% BSA) for 1 hour at room temperature. The coverslips were then
washed five times at 5-minute intervals with 0.1% saponin in PBSCM.
Cells were subsequently incubated with secondary antibodies diluted in
FDB for 1 hour at room temperature. The coverslips were washed
five times at 5-minute intervals with 0.1% saponin PBSCM and
then rinsed twice with PBSCM. The cells were then mounted on
microscopic slides with Vectashield mounting medium (Vector
Laboratories). Confocal microscopy was performed with Zeiss
AxioplanII microscope (Oberkochen, Germany) equipped with a Zeiss
confocal scanning optics.
Surface biotinylation and lectin binding
Cells were biotinylated twice (15–20 minutes each) on ice with 0.5 mg/ml
EZLinkH sulfo-NHS-biotin (sulfo-N-hydroxysuccinimidobiotin, Pierce).
The reaction was stopped by washing the cells four times (10 minutes
each) with 50 mM NH4Cl at 4 C˚ and then rinsing twice (10 minutes each)
with ice-cold PBSCM. The biotinylated cells were scraped off the plate and
then lysed in lysis buffer (25 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 1% BSA, 10% FBS, and 1 mM PMSF) at 4 C˚
with agitation for 1 hour. The extracts were centrifuged at 16,000 g for
10 minutes at 4 C˚. The supernatants were then incubated with streptavidin-
agarose (Pierce) at 4 C˚ for 2 hours. After washing once with lysis buffer,
three times with buffer A (25 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.5%
Triton X-100, and 1 mM PMSF), and three times with buffer B (10 mM
Tris-HCl pH 7.5, 150 mM NaCl), the beads were then eluted by boiling
for 5 minutes in 26 Laemmli sample buffer, without Coomassie Blue
and DTT. The eluted samples were then diluted in 4 ml lectin binding
buffer (40 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, and 1 mM MnCl2) and then incubated with lectin–agarose at 4 C˚
for 2 hours. The beads were then washed extensively, boiled in 26
Laemmli sample buffer for 5 minutes and analyzed by SDS-PAGE and
western blotting.
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Immunoprecipitation
Cells on tissue culture dishes were lysed in lysis buffer [50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, complete
EDTA-free protease inhibitors and protein phosphatase inhibitors
(Roche Diagnostics)]. The lysate was incubated on ice for 30 minutes
and cleared by centrifugation at 16,000 g for 30 minutes at 4 C˚.
Immunoprecipitation was carried out at 4 C˚ with 5 mg of antibody in the
presence of either Protein A or Protein G Sepharose 4 Fast Flow (GE
Healthcare) for 4 hours with rotation. The sepharose was then washed
five times with cell lysis buffer and twice with cold PBS. Bound proteins
were eluted with 26 Laemmli sample buffer, resolved by SDS-PAGE
and transferred onto PVDF membrane (Millipore) for subsequent
immunodetection.
In vitro translation and binding experiments
The TNT T7 Quick Coupled Transcription/Translation System (Promega)
and the 1-Step Human Coupled in vitro Protein Expression Kit (Thermo
Scientific) were used for in vitro translation according to the manufacturer’s
protocol. The translated products were combined in cell lysis buffer and
subjected to FLAG immunoprecipitation. The precipitates were then
washed five times with cell lysis buffer containing either 150 mM or
500 mM NaCl and twice with cold PBS. Bound proteins were eluted with
26Laemmli sample buffer, resolved by SDS-PAGE and transferred onto
PVDF membrane (Millipore) for subsequent immunodetection.
Acknowledgements
We thank Lihui Goh (Institute of Molecular Cell Biology, Singapore) and Sayan
Chakraborty (Institute of Molecular Cell Biology, Singapore) for their active
discussions and inputs.
Competing interests
The authors declare no competing interests.
Author contributions
Y.S.O and T.H.T.T. contributed equally to this work and wrote the main paper with
input from W.H. Electron microscopy was performed by N.V.G.
Funding
This work was supported by the Agency for Science, Technology and Research
(A*STAR), Singapore. Deposited in PMC for immediate release.
Supplementary material
Supplementary material available online at
http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.136754/-/DC1
References
Bard, F., Mazelin, L., Pe´choux-Longin, C., Malhotra, V. and Jurdic, P.
(2003). Src regulates Golgi structure and KDEL receptor-dependent
retrograde transport to the endoplasmic reticulum. J. Biol. Chem. 278, 46601-
46606.
Bascom, R. A., Srinivasan, S. and Nussbaum, R. L. (1999). Identification and
characterization of golgin-84, a novel Golgi integral membrane protein with a
cytoplasmic coiled-coil domain. J. Biol. Chem. 274, 2953-2962.
Bianchi, P., Fermo, E., Vercellati, C., Boschetti, C., Barcellini, W., Iurlo, A.,
Marcello, A. P., Righetti, P. G. and Zanella, A. (2009). Congenital
dyserythropoietic anemia type II (CDAII) is caused by mutations in the
SEC23B gene. Hum. Mutat. 30, 1292-1298.
Brockhausen, I. (2006). Mucin-type O-glycans in human colon and breast cancer:
glycodynamics and functions. EMBO Rep. 7, 599-604.
Campadelli, G., Brandimarti, R., Di Lazzaro, C., Ward, P. L., Roizman, B. and
Torrisi, M. R. (1993). Fragmentation and dispersal of Golgi proteins and
redistribution of glycoproteins and glycolipids processed through the Golgi
apparatus after infection with herpes simplex virus 1. Proc. Natl. Acad. Sci. USA
90, 2798-2802.
Cancino, J. and Luini, A. (2013). Signaling circuits on the Golgi complex. Traffic
14, 121-134.
Chia, P. Z. and Gleeson, P. A. (2011). The regulation of endosome-to-Golgi
retrograde transport by tethers and scaffolds. Traffic 12, 939-947.
Colley, K. J. (1997). Golgi localization of glycosyltransferases: more questions
than answers. Glycobiology 7, 1-13.
de Albuquerque Garcia Redondo, P., Nakamura, C. V., de Souza, W. and
Morgado-Dı´az, J. A. (2004). Differential expression of sialic acid and N-
acetylgalactosamine residues on the cell surface of intestinal epithelial cells
according to normal or metastatic potential. J. Histochem. Cytochem. 52, 629-
640.
Diaz, R. and Stahl, P. D. (1989). Digitonin permeabilization procedures for
the study of endosome acidification and function. Methods Cell Biol. 31, 25-
43.
Eckhardt, M., Gotza, B. and Gerardy-Schahn, R. (1999). Membrane topology
of the mammalian CMP-sialic acid transporter. J. Biol. Chem. 274, 8779-8787.
Foulquier, F. (2009). COG defects, birth and rise! Biochim. Biophys. Acta 1792,
896-902.
Foulquier, F., Vasile, E., Schollen, E., Callewaert, N., Raemaekers, T.,
Quelhas, D., Jaeken, J., Mills, P., Winchester, B., Krieger, M. et al. (2006).
Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously
uncharacterized congenital disorder of glycosylation type II. Proc. Natl. Acad.
Sci. USA 103, 3764-3769.
Foulquier, F., Ungar, D., Reynders, E., Zeevaert, R., Mills, P., Garcı´a-Silva,
M. T., Briones, P., Winchester, B., Morelle, W., Krieger, M. et al. (2007). A new
inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for
the Cog1-Cog8 interaction in COG complex formation. Hum. Mol. Genet. 16,
717-730.
Foulquier, F., Amyere, M., Jaeken, J., Zeevaert, R., Schollen, E., Race, V.,
Bammens, R., Morelle, W., Rosnoblet, C., Legrand, D. et al. (2012).
TMEM165 deficiency causes a congenital disorder of glycosylation. Am.
J. Hum. Genet. 91, 15-26.
Freeze, H. H. and Ng, B. G. (2011). Golgi glycosylation and human inherited
diseases. Cold Spring Harb. Perspect. Biol. 3, a005371.
Fu¨llekrug, J., Suganuma, T., Tang, B. L., Hong, W., Storrie, B. and Nilsson, T.
(1999). Localization and recycling of gp27 (hp24gamma3): complex formation
with other p24 family members. Mol. Biol. Cell 10, 1939-1955.
Gill, D. J., Chia, J., Senewiratne, J. and Bard, F. (2010). Regulation of O-
glycosylation through Golgi-to-ER relocation of initiation enzymes. J. Cell Biol.
189, 843-858.
Gill, D. J., Clausen, H. and Bard, F. (2011). Location, location, location:
new insights into O-GalNAc protein glycosylation. Trends Cell Biol. 21, 149-
158.
Glick, B. S. and Nakano, A. (2009). Membrane traffic within the Golgi apparatus.
Annu. Rev. Cell Dev. Biol. 25, 113-132.
Guillard, M., Dimopoulou, A., Fischer, B., Morava, E., Lefeber, D. J., Kornak,
U. and Wevers, R. A. (2009). Vacuolar H+-ATPase meets glycosylation in
patients with cutis laxa. Biochim. Biophys. Acta 1792, 903-914.
Hakomori, S. (2002). Glycosylation defining cancer malignancy: new wine in an
old bottle. Proc. Natl. Acad. Sci. USA 99, 10231-10233.
Hakomori, S. I. and Cummings, R. D. (2012). Glycosylation effects on cancer
development. Glycoconj. J. 29, 565-566.
Hang, H. C. and Bertozzi, C. R. (2005). The chemistry and biology of mucin-type
O-linked glycosylation. Bioorg. Med. Chem. 13, 5021-5034.
Hirst, J., Borner, G. H., Harbour, M. and Robinson, M. S. (2005). The aftiphilin/
p200/gamma-synergin complex. Mol. Biol. Cell 16, 2554-2565.
Itzkowitz, S. H., Bloom, E. J., Kokal, W. A., Modin, G., Hakomori, S. and Kim,
Y. S. (1990). Sialosyl-Tn. A novel mucin antigen associated with prognosis in
colorectal cancer patients. Cancer 66, 1960-1966.
Ivanova, A. V., Vortmeyer, A., Ivanov, S. V., Nickerson, M. L., Maher, E. R. and
Lerman, M. I. (2008). Loss of PL6 protein expression in renal clear cell
carcinomas and other VHL-deficient tumours. J. Pathol. 214, 46-57.
Kim, D. W., Massey, T., Sacher, M., Pypaert, M. and Ferro-Novick, S. (2001).
Sgf1p, a new component of the Sec34p/Sec35p complex. Traffic 2, 820-
830.
Kirschmann, D. A., Seftor, E. A., Nieva, D. R., Mariano, E. A. and Hendrix,
M. J. (1999). Differentially expressed genes associated with the metastatic
phenotype in breast cancer. Breast Cancer Res. Treat. 55, 125-134.
Kjer-Nielsen, L., van Vliet, C., Erlich, R., Toh, B. H. and Gleeson, P. A. (1999).
The Golgi-targeting sequence of the peripheral membrane protein p230. J. Cell
Sci. 112, 1645-1654.
Kranz, C., Ng, B. G., Sun, L., Sharma, V., Eklund, E. A., Miura, Y., Ungar, D.,
Lupashin, V., Winkel, R. D., Cipollo, J. F. et al. (2007). COG8 deficiency
causes new congenital disorder of glycosylation type IIh. Hum. Mol. Genet. 16,
731-741.
Kudlyk, T., Willett, R., Pokrovskaya, I. D. and Lupashin, V. (2013). COG6
interacts with a subset of the Golgi SNAREs and is important for the Golgi
complex integrity. Traffic 14, 194-204.
Laufman, O., Kedan, A., Hong, W. and Lev, S. (2009). Direct interaction between
the COG complex and the SM protein, Sly1, is required for Golgi SNARE
pairing. EMBO J. 28, 2006-2017.
Laufman, O., Hong, W. and Lev, S. (2011). The COG complex interacts directly
with Syntaxin 6 and positively regulates endosome-to-TGN retrograde transport.
J. Cell Biol. 194, 459-472.
Laufman, O., Hong, W. and Lev, S. (2013). The COG complex interacts with
multiple Golgi SNAREs and enhances fusogenic assembly of SNARE
complexes. J. Cell Sci. 126, 1506-1516.
Lees, J. A., Yip, C. K., Walz, T. and Hughson, F. M. (2010). Molecular
organization of the COG vesicle tethering complex. Nat. Struct. Mol. Biol. 17,
1292-1297.
Ley, K. and Kansas, G. S. (2004). Selectins in T-cell recruitment to non-lymphoid
tissues and sites of inflammation. Nat. Rev. Immunol. 4, 325-336.
Lieu, Z. Z. and Gleeson, P. A. (2011). Endosome-to-Golgi transport pathways in
physiological processes. Histol. Histopathol. 26, 395-408.
Loh, E. and Hong, W. (2004). The binary interacting network of the conserved
oligomeric Golgi tethering complex. J. Biol. Chem. 279, 24640-24648.
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 2825–2839 doi:10.1242/jcs.136754
2838
Jo
ur
na
l o
f C
el
l S
ci
en
ce
Lotan, R., Skutelsky, E., Danon, D. and Sharon, N. (1975). The purification,
composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea).
J. Biol. Chem. 250, 8518-8523.
Lu, L., Tai, G. and Hong, W. (2004). Autoantigen Golgin-97, an effector of Arl1
GTPase, participates in traffic from the endosome to the trans-golgi network.
Mol. Biol. Cell 15, 4426-4443.
Maupin, K. A., Liden, D. and Haab, B. B. (2012). The fine specificity of mannose-
binding and galactose-binding lectins revealed using outlier motif analysis of
glycan array data. Glycobiology 22, 160-169.
Miller, V. J. and Ungar, D. (2012). Re’COG’nition at the Golgi. Traffic 13, 891-897.
Molin, K., Fredman, P. and Svennerholm, L. (1986). Binding specificities of the
lectins PNA, WGA and UEA I to polyvinylchloride-adsorbed glycosphingolipids.
FEBS Lett. 205, 51-55.
Nagata, Y. and Burger, M. M. (1974). Wheat germ agglutinin. Molecular
characteristics and specificity for sugar binding. J. Biol. Chem. 249, 3116-3122.
Nakamori, T., Morimoto, A., Yamaguchi, K., Watanabe, T., Long, N. C. and
Murakami, N. (1993). Organum vasculosum laminae terminalis (OVLT) is a
brain site to produce interleukin-1 beta during fever. Brain Res. 618, 155-159.
Nakamura, N., Rabouille, C., Watson, R., Nilsson, T., Hui, N., Slusarewicz, P.,
Kreis, T. E. and Warren, G. (1995). Characterization of a cis-Golgi matrix
protein, GM130. J. Cell Biol. 131, 1715-1726.
Ng, B. G., Sharma, V., Sun, L., Loh, E., Hong, W., Tay, S. K. and Freeze, H. H.
(2011). Identification of the first COG-CDG patient of Indian origin. Mol. Genet.
Metab. 102, 364-367.
Ogata, S., Koganty, R., Reddish, M., Longenecker, B. M., Chen, A., Perez, C.
and Itzkowitz, S. H. (1998). Different modes of sialyl-Tn expression during
malignant transformation of human colonic mucosa. Glycoconj. J. 15, 29-35.
Oka, T., Ungar, D., Hughson, F. M. and Krieger, M. (2004). The COG and COPI
complexes interact to control the abundance of GEARs, a subset of Golgi
integral membrane proteins. Mol. Biol. Cell 15, 2423-2435.
Ono, M. and Hakomori, S. (2004). Glycosylation defining cancer cell motility and
invasiveness. Glycoconj. J. 20, 71-78.
Paciotti, G. F. and Tamarkin, L. (1988). Interleukin-2 differentially affects the
proliferation of a hormone-dependent and a hormone-independent human
breast cancer cell line in vitro and in vivo. Anticancer Res. 8, 1233-1239.
Ponnambalam, S., Girotti, M., Yaspo, M. L., Owen, C. E., Perry, A. C.,
Suganuma, T., Nilsson, T., Fried, M., Banting, G. and Warren, G. (1996).
Primate homologues of rat TGN38: primary structure, expression and functional
implications. J. Cell Sci. 109, 675-685.
Prescott, A. R., Lucocq, J. M., James, J., Lister, J. M. and Ponnambalam, S.
(1997). Dist inct compartmental izat ion of TGN46 and beta 1,4-
galactosyltransferase in HeLa cells. Eur. J. Cell Biol. 72, 238-246.
Rabouille, C., Hui, N., Hunte, F., Kieckbusch, R., Berger, E. G., Warren, G. and
Nilsson, T. (1995). Mapping the distribution of Golgi enzymes involved in the
construction of complex oligosaccharides. J. Cell Sci. 108, 1617-1627.
Rambaruth, N. D., Greenwell, P. and Dwek, M. V. (2012). The lectin Helix
pomatia agglutinin recognizes O-GlcNAc containing glycoproteins in human
breast cancer. Glycobiology 22, 839-848.
Reynders, E., Foulquier, F., Annaert, W. and Matthijs, G. (2011). How Golgi
glycosylation meets and needs trafficking: the case of the COG complex.
Glycobiology 21, 853-863.
Richardson, B. C., Smith, R. D., Ungar, D., Nakamura, A., Jeffrey, P. D.,
Lupashin, V. V. and Hughson, F. M. (2009). Structural basis for a human
glycosylation disorder caused by mutation of the COG4 gene. Proc. Natl. Acad.
Sci. USA 106, 13329-13334.
Rosnoblet, C., Legrand, D., Demaegd, D., Hacine-Gherbi, H., de Bettignies,
G., Bammens, R., Borrego, C., Duvet, S., Morsomme, P., Matthijs, G. et al.
(2013a). Impact of disease-causing mutations on TMEM165 subcellular
localization, a recently identified protein involved in CDG-II. Hum. Mol. Genet.
22, 2914-2928.
Rosnoblet, C., Peanne, R., Legrand, D. and Foulquier, F. (2013b). Glycosylation
disorders of membrane trafficking. Glycoconj. J. 30, 23-31.
Schaub, B. E., Berger, B., Berger, E. G. and Rohrer, J. (2006). Transition of
galactosyltransferase 1 from trans-Golgi cisterna to the trans-Golgi network is
signal mediated. Mol. Biol. Cell 17, 5153-5162.
Seaman, M. N. (2004). Cargo-selective endosomal sorting for retrieval to the Golgi
requires retromer. J. Cell Biol. 165, 111-122.
Seaman, M. N. (2008). Endosome protein sorting: motifs and machinery. Cell. Mol.
Life Sci. 65, 2842-2858.
Seaman, M. N. (2009). Enhanced SnapShot: endosome-to-golgi retrieval. Cell
139, 1198-1198.e1.
Sharon, N. (1983). Lectin receptors as lymphocyte surface markers. Adv.
Immunol. 34, 213-298.
Sheikh, K. A., Deerinck, T. J., Ellisman, M. H. and Griffin, J. W. (1999). The
distribution of ganglioside-like moieties in peripheral nerves. Brain 122, 449-460.
Sheldon, P. S., Keen, J. N. and Bowles, D. J. (1998). Purification and
characterization of N-glycanase, a concanavalin A binding protein from
jackbean (Canavalia ensiformis). Biochem. J. 330, 13-20.
Smith, R. D. and Lupashin, V. V. (2008). Role of the conserved oligomeric Golgi
(COG) complex in protein glycosylation. Carbohydr. Res. 343, 2024-2031.
Spaapen, L. J., Bakker, J. A., van der Meer, S. B., Sijstermans, H. J., Steet,
R. A., Wevers, R. A. and Jaeken, J. (2005). Clinical and biochemical
presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-
glycosylation disorder. J. Inherit. Metab. Dis. 28, 707-714.
Steet, R. and Kornfeld, S. (2006). COG-7-deficient human fibroblasts exhibit
altered recycling of golgi proteins. Mol. Biol. Cell 17, 2312-2321.
Tang, D. and Wang, Y. (2013). Cell cycle regulation of Golgi membrane dynamics.
Trends Cell Biol. 23, 296-304.
Tang, B. L., Low, S. H., Hauri, H. P. and Hong, W. (1995). Segregation of
ERGIC53 and the mammalian KDEL receptor upon exit from the 15 degrees C
compartment. Eur. J. Cell Biol. 68, 398-410.
Tarp, M. A. and Clausen, H. (2008). Mucin-type O-glycosylation and its potential
use in drug and vaccine development. Biochim. Biophys. Acta 1780, 546-563.
Tian, E. and Ten Hagen, K. G. (2009). Recent insights into the biological roles of
mucin-type O-glycosylation. Glycoconj. J. 26, 325-334.
Townsley, F. M., Wilson, D. W. and Pelham, H. R. (1993). Mutational analysis of
the human KDEL receptor: distinct structural requirements for Golgi retention,
ligand binding and retrograde transport. EMBO J. 12, 2821-2829.
Ungar, D., Oka, T., Krieger, M. and Hughson, F. M. (2006). Retrograde transport
on the COG railway. Trends Cell Biol. 16, 113-120.
Velasco, F., Velasco, M., Ma´rquez, I. and Velasco, G. (1993). Role of the
centromedian thalamic nucleus in the genesis, propagation and arrest of
epileptic activity. An electrophysiological study in man. Acta Neurochir. Suppl.
(Wien) 58, 201-204.
Virtanen, I. (1990). Helix pomatia agglutinin binds specifically to the Golgi
apparatus in cultured human fibroblasts and reveals two Golgi apparatus-
specific glycoproteins. Histochemistry 94, 397-401.
Walter, D. M., Paul, K. S. and Waters, M. G. (1998). Purification and
characterization of a novel 13 S hetero-oligomeric protein complex that
stimulates in vitro Golgi transport. J. Biol. Chem. 273, 29565-29576.
Willett, R., Kudlyk, T., Pokrovskaya, I., Scho¨nherr, R., Ungar, D., Duden, R.
and Lupashin, V. (2013). COG complexes form spatial landmarks for distinct
SNARE complexes. Nat. Commun. 4, 1553.
Wu, X., Steet, R. A., Bohorov, O., Bakker, J., Newell, J., Krieger, M., Spaapen,
L., Kornfeld, S. and Freeze, H. H. (2004). Mutation of the COG complex
subunit gene COG7 causes a lethal congenital disorder. Nat. Med. 10, 518-
523.
Wuestehube, L. J., Duden, R., Eun, A., Hamamoto, S., Korn, P., Ram, R. and
Schekman, R. (1996). New mutants of Saccharomyces cerevisiae affected in
the transport of proteins from the endoplasmic reticulum to the Golgi complex.
Genetics 142, 393-406.
Zeevaert, R., Foulquier, F., Jaeken, J. and Matthijs, G. (2008). Deficiencies in
subunits of the Conserved Oligomeric Golgi (COG) complex define a novel
group of congenital disorders of glycosylation. Mol. Genet. Metab. 93, 15-21.
Zeevaert, R., de Zegher, F., Sturiale, L., Garozzo, D., Smet, M., Moens, M.,
Matthijs, G. and Jaeken, J. (2013). Bone dysplasia as a key feature in three
patients with a novel Congenital Disorder of Glycosylation (CDG) Type II due to
a deep intronic splice mutation in TMEM165. JIMD Rep. 8, 145-152.
Zolov, S. N. and Lupashin, V. V. (2005). Cog3p depletion blocks vesicle-mediated
Golgi retrograde trafficking in HeLa cells. J. Cell Biol. 168, 747-759.
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 2825–2839 doi:10.1242/jcs.136754
2839
